4.7 Article

Protein Markers of Neurotransmitter Synthesis and Release in Postmortem Schizophrenia Substantia Nigra

期刊

NEUROPSYCHOPHARMACOLOGY
卷 42, 期 2, 页码 540-550

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2016.164

关键词

-

资金

  1. National Institute of Mental Health [F31MH098566, RO1MH066123]

向作者/读者索取更多资源

The substantia nigra (SN) provides the largest dopaminergic input to the brain, projects to the striatum (the primary locus of action for antipsychotic medication), and receives GABAergic and glutamatergic inputs. This study used western blot analysis to compare protein levels of tyrosine hydroxylase (TH), glutamate decarboxylase (GAD67), and vesicular glutamate transporters (vGLUT1 and vGLUT2) in postmortem human SN in schizophrenia subjects (n = 13) and matched controls (n = 12). As a preliminary analysis, the schizophrenia group was subdivided by (I) treatment status: off medication (n = 4) or on medication (n = 9); or (2) treatment response: treatment resistant (n = 5) or treatment responsive (n = 4). The combined schizophrenia group had higher TH and GAD67 protein levels than controls (an increase of 69.6%, P = 0.01 and 19.5%, P = 0.004, respectively). When subdivided by medication status, these increases were found in the on -medication subjects (TH 88.3%, P = 0.008; GAD67 40.6%, P = 0.003). In contrast, unmedicated schizophrenia subjects had higher vGLUT2 levels than controls (an increase of 28.7%, P = 0.04 I), but vGLUT2 levels were similar between medicated schizophrenia subjects and controls. Treatment-resistant subjects had significantly higher TH and GAD67 levels than controls (an increase of 121.0%, P = 0.0003 and 58.7%, P = 0.004, respectively). These data suggest increases in dopamine and GABA transmission in the SN in schizophrenia, with a potential relation to treatment and response.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据